Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 9Nivolumab 4Fluorouracil 4Mohs Surgery 3talimogene laherparepvec 2atezolizumab 2Therapeutics 2Photochemotherapy 2Petrolatum 2Paclitaxel 2Niacinamide 2Aminolevulinic Acid 2tozuleristide 1smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1selinexor 1regorafenib 1peginterferon alfa-2b 1peginterferon alfa-2a 1osimertinib 1nanocis 1methyl 5-aminolevulinate 1fludarabine 1daromun 1cobimetinib 1cemiplimab 1avelumab 1aldesleukin 1aflibercept 1afamelanotide 1Vitamin D 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × nanocis × Dermatologic × Clear all
NCT02997553 2023-01-09

GASVERT

Institut de Cancérologie de Lorraine

Phase 3 Completed
744 enrolled
BreastDermatologicGastrointestinalGynecologicHead & Neck

Anus Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡